Fortress Biotech, Inc.
FBIOPHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Fortress Biotech, Inc. focuses on Biotechnology services and products. Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squam.
Market Cap
—
Beta
1.19
P/E (TTM)
—
P/E (Fwd)
—
EPS (TTM)
$-0.86
EPS (Fwd)
—
ROE
116.0%
ROA
-7.8%
Cash
$196.6M
Total Debt
$53.3M
Free CF
-$17.1M
52W Change
104.9%
Annual Financials
Cash vs Debt
Where FBIOP stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FBIOP finished 15.41% above its 150-day moving average ($16.22) and 29.37% above its 200-day moving average ($14.47). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FBIOP overbought or oversold?
At the September 3, 2026 close, FBIOP's RSI(14) was 41.3, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $196.6M in cash comfortably exceeding the $53.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$17.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of 116.0% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $75.7M to $63.3M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FBIOP.